ITCH RELIEF

Name: Nemluvio HCP
Creator: Nemluvio

NEMLUVIO delivered fast and lasting itch relief in the ARCADIA clinical trials^1,2

Itch relief as soon as

48

hours

in some patients¹*

Consistent results were seen in
ARCADIA 1 and ARCADIA 2¹

PP-NRS response was achieved at 48 hours in 10.7% of patients with NEMLUVIO +TCS/TCI vs 2.9% with placebo +TCS/TCI. Data are from pooled post-hoc analysis of daily PP‑NRS improvement reported in Phase 3 clinical studies (ARCADIA 1 and ARCADIA 2). PP‑NRS response defined as a ≥4‑point improvement from baseline. No conclusions regarding efficacy should be made based on these results.¹

Actor portrayal.

More than 8 out of 10 patients taking NEMLUVIO experienced lasting itch relief with over 2 years of treatment²

Observed cases of ≥4-point improvement in the Pruritus VAS component of SCORAD in ARCADIA LTE interim analysis at Week 104.²

REVIEW STUDY DESIGN

~70%

of patients taking NEMLUVIO + TCS/TCI were itch-free or nearly itch-free with 2 years of treatment^2†

Data based on interim analysis proportion of NEMLUVIO-naïve patients with Pruritus VAS <2 at Week 104 of the ARCADIA LTE.²

Experiencing a new reality

See how Chris and Whitney relieved their unrelenting itch and achieved lasting skin healing with NEMLUVIO.

Transcript

Since starting the NEMLUVIO, I'm not itchy. Within two days I had noticed a significant improvement in the itch after starting the NEMLUVIO, and at that point it was pretty much gone.

I would definitely say that my disease was managed with NEMLUVIO at 4 weeks. My hands weren't cracked anymore, the areas around my eyes had healed.

The change has been hard to believe. In a good way. Basically, before the shot, itching was part of my reality.

I have not been itching since the first shot. After 1 month on NEMLUVIO, I have seen significant improvement in my itch.

Favorable Safety Profile³

NEMLUVIO was well tolerated, has no boxed warning, and requires no preliminary lab evaluations or ongoing lab monitoring³

REVIEW SAFETY PROFILE

Q4W Dosing From the Start³

NEMLUVIO is the only biologic approved for AD with Q4W dosing from the start^3-5

LEARN MORE

Sign up now for more information about NEMLUVIO for AD

SIGN UP

AD=atopic dermatitis; EASI=Eczema Area and Severity Index; LTE=long-term extension; PP-NRS=Peak Pruritus Numerical Rating Scale; Q4W=every 4 weeks; SCORAD=Scoring Atopic Dermatitis; TCI=topical calcineurin inhibitor; TCS=topical corticosteroid; VAS=visual analog scale.

References: 1. Ständer S, Elmariah SB, Kwatra SG, et al. Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies. J Eur Acad Dermatol Venereol. 2025;00:1‑9. doi:10.1111/jdv.70250 2. Augustin M, Tauber M, Sidbury R, et al. Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study. J Eur Acad Dermatol Venereol. 2025;00:1–15. doi:10.1111/jdv.70080 3. NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information. Dallas, TX: Galderma Laboratories, L.P. 4. DUPIXENT Prescribing Information. Sanofi and Regeneron Pharmaceuticals, Inc.; 2024. 5. EBGLYSS Prescribing Information. Lilly USA, LLC.; 2024.

IMPORTANT SAFETY INFORMATION

INDICATIONS: NEMLUVIO^® (nemolizumab-ilto) is an interleukin-31 receptor alpha antagonist indicated for:

the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.
the treatment of adults with prurigo nodularis.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

WARNINGS AND PRECAUTIONS:
Hypersensitivity reactions have been reported with NEMLUVIO use. If clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO.

ADVERSE REACTIONS:
Most common adverse reactions (incidence ≥1%) are:

Atopic Dermatitis: headache (including migraine), arthralgia, urticaria, and myalgia.
Prurigo Nodularis: headache, dermatitis atopic, eczema, and eczema nummular.

USE IN SPECIFIC POPULATIONS:
Pregnancy: There are no adequate and well-controlled studies on NEMLUVIO in pregnant women. The limited available information on NEMLUVIO use during pregnancy is not sufficient to inform a drug- associated risk of major birth defects or miscarriage in humans. Human IgG antibodies are known to cross the placental barrier; therefore, NEMLUVIO may be transmitted from the mother to the developing fetus.

Lactation: There are no data on the presence or transfer of NEMLUVIO in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to NEMLUVIO on the breastfed infant are unknown. NEMLUVIO has not been administered to nursing/lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NEMLUVIO and any potential adverse effects on the breastfed child from NEMLUVIO or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of NEMLUVIO have not been established in pediatric patients younger than 12 years of age for the treatment of moderate-to-severe atopic dermatitis or pediatric patients younger than 18 years of age for the treatment of prurigo nodularis.

Please see full Prescribing Information, including Patient Information.